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Abstract
Background: Radiotherapy for retroperitoneal sarcomas remains controversial and a technical challenge
considering the threshold of contiguous critical organs tolerance. We performed consecutive RapidArc dosimetric
plans in preoperative or postoperative setting.
Methods: A dosimetric study was carried out from six preoperative (group A) and four postoperative (group B)
CT-scans, performed in 7 patients.
Prescribed dose was 45 and 50 Gy for groups A and B, respectively. The planning target volume (PTV) was defined
as the clinical target volume (CTV) plus 5 mm. The CTV encompassed the gross tumor volume (GTV) plus 10 mm
or the tumoral bed. The dosimetric plans were optimized on a RapidArc Eclipse console using the progressive
resolution algorithm, PRO version 8.8. Normalization method allowed the coverage of 99% of the PTV by 95% of
the dose.
Results: Mean PTV were 2318.5 ± 2223.9 cc [range 348-6198 cc] and 698.3 ± 216.6 cc [range 463 -933 cc] for
groups A and B, respectively. Plans were optimized for single arcs in group B and for single or two arcs in group A.
The contralateral kidney volume receiving 5 Gy (V5Gy) was 21.5 ± 23.3% [range 0-55%] and 3.1 ± 2.6% [range 0-
7.3%] for groups A and B, respectively. The mean dose received by 1% of the kidney (D1%) was 5.6 ± 2.4 Gy [range
3.6 -7.6 Gy] for group A and 5.4 ± 0.7 Gy [range 4.3-6 Gy] for group B. The volume of small bowel excluding the
PTV (small bowel-PTV) that received 40 Gy and 30 Gy (V40Gy and V30Gy) in group A were 7.5 ± 4.4% [range 5.4-
14.1%] and 18.5 ± 7.1% [range 10-30.4%], respectively.
In group B, small bowel-PTV V40Gy and V30Gy were 4.7 ± 3.3% [range 3.3-8%] and 21.6 ± 7.5% [range 9.4-30%]
respectively. In a second step, we treated two patients in the postoperative group. Treatment time delivery with
one arc was 74 seconds. No severe acute toxicity was observed.
Conclusion: RapidArc technology for retroperitoneal sarcomas showed acceptable dosimetric results in
preoperative or postoperative clinical situation. From the first treated patients, acute tolerability was good to
excellent.
Background
Retroperitoneal sarcoma is a rare and very heteroge-
neous disease representing about 10-15% of all soft tis-
sue sarcomas. Surgery is the main treatment, but
microscopic or gross residual disease may remain after
the procedure, compromising local control and survival
[1-4]. Since local progression rather than metastatic
dissemination is the main cause of death, the role of
radiotherapy in association to surgery has been investi-
gated. There are no randomized trials comparing post-
operative to preoperative radiotherapy and the
appropriate strategy is not well defined today.
Based on the results of phase III randomized trials for
limb soft tissue sarcoma, postoperative RT has been
adopted by some teams in retroperitoneal sarcomas.
Nevertheless, this approach raises the problem of the
tumor underdosing due to the nearby critical organs at
risk (OAR), with the consequence to increase the risk of
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authors who reported a high local relapse rate inside the
radiotherapy field with considerable toxicity, dissuading
postoperative radiotherapy [4-6].
The single randomized trial about adjuvant radiother-
apy in resectable retroperitoneal sarcomas [7,8] com-
pared a standard external beam radiotherapy (EBRT)
delivering 50-55 Gy to an experimental therapy that
associated a single dose (20 Gy) of intraoperative radio-
therapy (IORT) using electrons with a low dose post-
operative EBRT (35-40 Gy). With a median follow-up of
8 years, the number of locoregional recurrence was sig-
nificantly reduced in the experimental arm, as well as
the enteral toxicity.
Preoperative radiotherapy has some theoretical advan-
tages in the management of retroperitoneal sarcomas,
such as the reduction of tumor seeding during surgery
and the shift of radiosensitive viscera outside the treat-
ment field [9]. Prospective trials showed the feasibility of
preoperative radiotherapy in this context [10-12].
Regarding IMRT, it is now well established that this
technique usually provides high conformity and offers
improved OAR sparing when compared to 3 D confor-
mational radiotherapy. IMRT use has already been
investigated for the treatment of retroperitoneal sarco-
mas [13-15]. Although large fields may be required for
those tumors, more particularly in preoperative setting,
this does not preclude the employment of IMRT [14],
but the dose inhomogeneity within the target can
increase considerably, especially in the vicinity of kid-
n e y s .T oi m p r o v ed o s eh o m o g e n e i t yt h r o u g h o u tt h e
planning tumor volume (PTV), multiplying fields may
be necessary, having the effect to increase the treatment
time per fraction [16]. Some authors investigated the
feasibility of diminishing the size of fields to only irradi-
ate specifically the portion of the clinical tumor volume
(CTV) at the higher risk of relapse [13].
In this context, the purpose of this study was to assess
dosimetric aspects using RapidArc technology for the
treatment of retroperitoneal sarcoma. The feasibility of
volumetric arc therapy was evaluated in several dosi-
metric plans obtained before or after surgery. We used
two different dose levels (45 and 50 Gy) adapted to the
clinical situation, in order to protect normal tissues
including small bowel, contralateral kidney and spinal
cord and achieve an excellent coverage of the whole tar-
get volume. In addition, we investigated the opportunity
to deliver complex radiotherapy treatments in a short
treatment time. Finally, we directly implemented these
physical data into the clinic.
Methods
This dosimetric study was carried out from ten CT-
scans performed in a series of seven consecutive patients
with resectable retroperitoneal sarcoma. Patients under-
went either a single preoperative or postoperative CT-
scan or both exams, providing six preoperative (group
A) and four postoperative cases (group B). The dosi-
metric analysis was performed using RapidArc
technology.
Radiotherapy treatment planning
Patients underwent CT scan-based virtual simulation
(GE lightspeed RT16 Milwaukee, USA). Patients were
placed in supine position with the arms above the head,
using a special support (Sinmed, The Netherlands) and
knees were placed with a knee support (Sinmed, The
Netherlands). Intravenous contrast was not used consid-
ering that renal function of those patients could be
altered. 4DCT Scanner was performed to include tumor
motion during breathing with 2.5 mm thick slices at
2.5 mm intervals. Tumor (GTV) or tumor bed were
manually contoured on the CT images. The isocenter
was set in the middle of the GTV if preoperatively or
the tumoral bed if postoperatory, using our virtual simu-
lation console (Advantagesim, GE Milwaukee, USA). In
the case of preoperative radiotherapy (Group A), the
CTV included the tumor and a margin around obtained
by a three-dimensional 10 mm expansion, except poster-
iorly in regards of the vertebral body or bone, where the
margin was adapted to sculpt these structures. In the
postoperative planning (Group B), the CTV was defined
together by the surgeon and the radiation oncologist to
include the tumor bed and all the areas at risk. To
account for set-up inaccuracies, a PTV was defined by a
three-dimensional 5 mm expansion of CTV in all direc-
tions, except close to the spinal cord where it was
reduced if necessary. The PTV margin was chosen after
4DCT scanner evaluation.
Kidneys or contralateral kidney were completely con-
toured. A planning organ at risk volume (PRV) of 3 cm
was added to the contralateralk i d n e yf o rt w or e a s o n s :
first, because of the potential internal movement of this
structure and second, to be able to define a constraint
limiting the dose delivered around the kidney. Small
bowel and spinal cord were contoured from 2 cm above
to 2 cm below the extension of the tumor or the tumor
bed corresponding to the portion of the irradiated
organ. Liver was contoured as a whole organ when it
was close to the target volume.
T h ed o s ep r e s c r i b e dt ot h eP T Vw a s5 0a n d4 5G yi n
25 fractions for Groups A and B, respectively.
Dose constraints to the OAR were based on the avail-
able IMRT studies (Table 1). The maximal dose (Dmax)
allowed for the small bowel was the prescribed dose.
Dose received by 50% and 30% of the small bowel (SB
D50, SB D30) should not exceed 30 Gy and 40 Gy,
respectively. The maximal dose allowed to contralateral
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Page 2 of 10kidney was 12 Gy, but we systematically tried to mini-
mize global dose to the whole volume. Liver could
receive 20 Gy to the whole volume and 40 Gy to 30% of
the volume. The maximal tolerated dose to the spinal
cord was 45 Gy.
The RapidArc plan optimization was generated by the
progressive resolution optimizer (PRO) algorithm of the
Eclipse workstation (Varian Medical System, Palo Alto,
USA) in a version 8.8 allowing multiple arcs. Single or
double gantry rotation was used depending on the thick-
ness of the volume. Each arc had systematically an
counter-clockwise rotation of 358° from 179° to 181°
and opposite if two arcs. The beams shared the same
isocenter with different collimator rotation to increase
the modulation capacities of the algorithm.
Plan acceptance criteria required that at least 95% of
the dose covers 99% of the PTV volume.
Evaluation tools
Dose Volume Histograms (DVH) were generated to
evaluate the three different plans. For PTV, the para-
meters D1% and D99% were used as surrogate markers
for maximum and minimum doses. Mean dose (Dmean)
was also reported.
T h ed e g r e eo fc o n f o r m i t yo ft h ep l a n sw a sd e f i n e da s
the ratio between the volume receiving at least 95% of
the prescribed dose and the volume of the PTV (CI95%).
The homogeneity index (HI) was expressed by D5% -
D95% (difference between the dose covering 5% and 95%
of the PTV). For all patients DVH for OAR (bowel,
bowel excluding PTV, kidneys and spinal cord) were
calculated and reported. A set of Vx values and Dmean
was therefore reported. The number of Monitor Units
(MU) per fraction required for each plan and the treat-
ment delivery time (from start to the end of the
irradiation), dimension of the fields and collimator angle
are reported in Table 2.
Following the results of the study, the two last conse-
cutive patients of group B were treated by receiving
45 Gy.
Quality assurance for treated patients
We conducted a quality control of the dosimetric plans
regarding the 2 patients treated in this study. It con-
sisted in a comparison between the previous dose calcu-
lated by the planning system and the actual measured
dose delivered by the linac. Two different methods were
used. The first one consisted of calculating the plan in a
cylindrical phantom of 20 cm diameter and then mea-
suring the dose at the central point of this phantom by
an ionisation chamber of 0.125 cc (PTW, Freiburg, Ger-
many). The second method used an amorphous silicon
portal imager (AS1000 Varian Medical System, Plo Alto,
US) as a detection matrix with a resolution of 0.39 mm/
pixel at the machine isocenter. The dose collected was
compared to a previous distribution on water using the
GlaAs algorithm and the Epiqas o f t w a r e( E p i d o s ,B r t a i -
slavia, Slovakia)[17].
Results
Technical data are summarized in Table 2. Our cases
were characterized by very large target volumes invol-
ving wide fields until 36 cm of length. This resulted in a
low number of MU delivered (380.7 and 332.3 for
Groups A and B, respectively) due to a high output fac-
tor of the machine. Postoperative plans were optimized
for one arc, and some preoperative plans, specially those
with the largest PTV, required 2 arcs. Even in those
cases, the number of MU was not significantly
increased.
Table 1 Literature dose constrains for IMRT
Author n° cases preop postop dose to PTV (Gy) dose constraints (Gy)
contralateral kidney small bowel spinal cord liver
Tzeng [26] 16 16 0 45 ± 12,5 < 23 < 45 < 45 < 33
54 to <20 cc
Bossi [13] 18 18 0 50 < 10 to 50% V55Gy < 50% < 48 V50Gy < 33%
< 50 V30Gy < 100%
Koshy [14] 11 9 2 45-50,4 12 to 100% < 45
15 to 50% D75% 48 V40Gy < 50%
D50% 50 V30Gy < 100%
Present study 10 6 4 45-50 < 12 < 45-50 < 45
V40Gy <30% V40Gy <30%
V30Gy <50% V30Gy <40%
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Page 3 of 10For the treated patients, the treatment time was 74 sec-
onds using one arc. Quality control analysis showed
acceptable results with a difference between the calcu-
lated and measured doses of 1.2% and 1.7% in the
cylindrical phantom. Percentage of points meeting the
criteria of 3%-3 mm for the gamma index was 98.3%
and 95.7% for both patients.
Figure 1 and 2 shows examples of dose distribution
for the preoperative and postoperative cases. Dosimetric
data for PTV and OAR are recorded in table 3 and
DVH results are shown in figures 3 and 4. All plans
were normalized aiming to obtain V95% >9 9 %f o rt h e
PTV. When we evaluated GTV (preoperative cases)-
CTV (postoperative cases)D V Hi nF i g u r e3 ,w ec o u l d
observe that for all cases the dose distribution was
homogeneous. Nevertheless, homogeneity (represented
by D5%-D95%) inside the PTV could reach 12 and 18%
for the two largest volumes (6198 and 4085 cc) of the
preoperative group.
Concerning the OAR, the dose constraints initially
required (Table 1) were largely respected. With regards
to the bowel and bowel-PTV we presented the DVH
results for all cases, showing the important variability of
bowel volume from one case to another. V40Gy ranged
from 66.6 cc to 962.8 cc for group A and from 18.7 cc
to 695.3 cc for group B. Mean small bowel D1% was 53
±2 . 9G y ,w i t haD max of 59 Gy in the portion included
in the PTV for the largest tumor. The volume of small
bowel-PTV receiving the prescribed dose was always
below 3 cc.
Dose constraints were largely respected for the kidney
and the spinal cord.
Early clinical practice
Treated patients were 29 and 47 years old respectively,
and were diagnosed with a liposarcoma at the histologi-
cal examination. They did not present any comorbidity
factors. The treatment strategy was approved by a pluri-
disciplinar committee. PTV volumes were 933 and 463
cc, respectively. They underwent surgery combined to
IORT at a single dose of 15 Gy delivered by an 80 mm
diameter collimator, and then received postoperative
radiotherapy at a dose of 45 Gy in 25 fractions.
Acute toxicity was evaluated according to the Com-
mon Toxicology Criteria grading system (CTC V.03).
Both patients showed G1 nausea-vomiting. Pain and
neuropathy was G0 and no patient presented any skin
reactions or weight loss.
Discussion
IMRT for retroperitoneal sarcoma has already been stu-
died and implemented to clinical practice by some
teams. Dose constraints criteria of those series are
shown in Table 1. On the one hand, IMRT has proved a
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Page 4 of 10significant improvement of the PTV coverage when
compared to 3DCRT, achieving a better protection of
OAR, specially the small bowel (V30 43.1 ± 20.6% with
IMRT vs 63.5 ± 25.2% with 3DCRT) [14]. On the other
hand, the problem of IMRT for the treatment of impor-
tant volumes, as some retroperitoneal sarcomas, is the
difficulty to achieve a homogeneous dose distribution
inside the PTV, which is translated in hotspots around
OAR. To palliate this technical problem it is sometimes
necessary to multiply fields or adding segments, that
inevitably prolongs treatment delivery time. This implies
the increased possibility of positioning error and the
necessity of a trustworthy repositioning system, that is
sometimes very inconfortable for the patient [16].
Knowing that the highest risk of local relapse is limited
to the contact region between the tumor and the poster-
ior abdominal wall, Bossi et al [13] proposed a new
IMRT strategy in which the CTV was limited to this
A) 
 B) 
Figure 1 Conformity of IMRT using RapidArc in a postoperative case. A) Volume receiving 45 Gy (V45). B) Volume receiving 5 Gy (V5).
Contralateral kidney is completely spared.
Figure 2 Conformity of IMRT using RapidArc in a preoperative case. Dose distribution for a preoperative case. Colourwash is in the interval
from 5 to 50 Gy.
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Page 5 of 10area, reducing the volume of the target in an attempt to
decrease toxicity. IMRT plans were compared to
3DCRT and showed a significant better sparing with
IMRT of the contralateral kidney. No significant advan-
tage for small bowel was observed with IMRT in their
study where they defined the CTV as a part of the
whole GTV. Additionally, the presence of the tumor
shifted small bowel outside of the PTV.
Many authors reported for other tumor sites dosi-
metric plans at least similar for RapidArc when com-
pared to IMRT with a static gantry position [18-23].
RapidArc was implemented since 2008 in our institution
in a daily practice for several localisations. Therefore we
decided to evaluate this innovative technique for the
treatment of retroperitoneal sarcomas.
We found in the frame of our dosimetric study better
DVH results than those expected at the initial planning
time taking into account that we studied very large
volumes (Table 3). Our choice regarding the normaliza-
tion method was specific for this localisation. We initi-
ally decided to cover 99% of the PTV by 95% of the
prescribed dose. This resulted in a better dose coverage
in the edge of the volume, but compromised homogene-
ity, particularly for the largest preoperative case, where
we obtained a maximal dose of 124% inside the PTV.
This hotspot wouldn’t have been observed if we had
c o v e r e d9 5 %o ft h ev o l u m eb y9 5 %o ft h ed o s e .N e v e r -
theless, we may wonder whether the presence of these
hotspots inside the PTV is really problematic knowing
that this lesion will be removed.
Regarding the organs at risk, small bowel DVH
showed that V30Gy and V40Gy results were better than
initially required for both groups. Hotspots in the small
bowel were systematically in the portion included in the
PTV for the biggest case. The portion of bowel - PTV
irradiated above the prescribed dose was always very
limited (< 3cc).
To allow reproducible correlation between the volume
of small bowel receiving a dose range and toxicity, DVH
data were expressed in cc. Some authors showed that a
V30Gy > 450 cc was correlated to a significant higher
acute gastro-intestinal (GI) toxicity [24] and that when
Table 3 Dosimetric results for PTV and OAR
Preoperative Postoperative
MEAN SD MAX MIN MEAN SD MAX MIN
PTV
Volume [cc] 2318,5 2223,9 6198,0 348,0 698,3 216,6 933,0 463,0
D1% [%] 111,2 6,7 124,0 103,4 105,3 2,4 109,1 103,1
D95% [%] 99,3 2,3 103,9 96,8 97,5 0,4 98,2 97,3
D5% [Gy] 109,4 6,2 121,8 102,5 104,5 2,0 107,6 102,6
V107% [%] 25,6 30,9 90,0 0,0 2,1 3,6 8,3 0,0
V95% [%] 99,0 0,0 99,0 99,0 99,0 0,0 99,0 99,0
D5%-D95% [%] 10,1 4,1 17,9 5,7 6,9 1,7 9,4 5,3
CI 95% 1,1 0,1 1,2 1,1 1,2 0,0 1,3 1,2
Spinal Cord
D1% [Gy] 28,1 12,6 40,0 1,9 32,6 4,4 39,2 28,1
Dmax [Gy] 32,0 13,6 44,0 3,1 35,0 4,8 41,0 30,0
Kidney
Volume [cc] 149,9 60,1 173,8 105,2 171,6 31,6 209,6 139,0
V5 Gy [%] 21,5 23,3 55,0 0,0 3,1 2,6 7,3 0,0
Dmean [Gy] 3,5 1,9 5,2 1,4 2,9 0,5 3,8 2,5
D1% [Gy] 5,6 2,4 7,6 3,6 5,4 0,7 6,0 4,3
Bowel
Volume [cc] 1421,3 729,7 2720,0 628,8 1494,9 533,7 2406,0 1105,0
V30Gy [%] 33,2 12,0 50,9 19,0 30,5 11,5 43,0 11,9
V40Gy [%] 22,4 9,1 35,4 10,6 15,6 9,6 28,9 1,7
D1% [Gy] 53,4 2,9 59,6 50,7 46,9 0,8 47,7 45,7
V Prescription dose [%] 12,2 9,2 28,0 2,8 8,7 7,7 21,0 0,0
Bowel-PTV
Volume [cc] 1183,6 645,3 2392,0 481,4 1343,7 613,2 2205,0 825,2
V30Gy [%] 18,5 7,1 30,5 10,1 21,6 7,5 30,0 9,4
V40Gy [%] 7,5 4,4 14,1 1,3 4,7 3,3 8,0 0,0
V Prescription dose [%] 0,6 0,9 2,2 0,0 0,7 1,3 2,9 0,0
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Page 6 of 10small bowel - PTV V40Gy exceeded 200 cc, there was a
10% probability to develop G2-3 acute GI toxicity [25].
Tzeng [26] treated 16 patients with retroperitoneal sar-
coma at a dose of 45 Gy in 25 fractions using IMRT
with a boost of 12.5 Gy to the areas at theoretical risk
of positive margin after resection. The only patient
showing G3 GI toxicity had received 54 Gy to more
than 20 cc of small bowel, recommending that this con-
straint should be respected. Our small bowel DVH
results always remained under these levels.
Kidney tolerance doses to whole organ irradiation
DT5/5 and 50/5, are 23 and 28 Gy, respectively [27]. It
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Figure 3 Dose Volume Histograms for PTV (all cases), CTV(postoperative cases) and GTV (preoperative cases).
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Page 7 of 10has been reported that in the absence of concomitant
chemotherapy or latent nephropathy, doses under 15 Gy
are not likely to provoke radiation-induced nephropathy
[28]. Another important concept is that kidney consists
of multiple independent functional structures very sensi-
tive to radiation. For this reason, despite the problem of
total dose, there is the problem of quantity of irradiated
volume even at low doses. May et al [29] showed that
the percentage of bilateral renal volume receiving at
least 10 Gy and the mean kidney dose were significant
predictors of subsequent G2 renal complications (p =
0.017 and p = 0.0095 respectively).
In our study respectively mean and maximal doses
received by the contralateral kidney were 3.45 Gy and
7.6 Gy for the preoperative and 2.94 Gy and 6 Gy for
the postoperative plans, which is much lower than
accepted doses. One could be worried about the respira-
tion-induced motion of the kidneys making uncertain
the doses received. Some authors studied this phenom-
enon showing a maximal movement of kidneys in
cephalo-caudal direction, with displacements varying
around 16 ± 8 mm [30,31] justifying the PRV of 3 cm
that we created around this structure to allow respect of
dose constraints. Furthermore, as those patients will be
monorenal in most of the cases, we recommend the pre-
scription of a pre-treatment renal scintigraphy to asses
the functionality of the remaining kidney.
Concerning the dose for retroperitoneal sarcomas,
limitation of dose prescription was assessed by the toler-
ance of the organs at risk. Our results open the question
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Figure 4 Dose Volume Histograms (DVH) for OAR. A) mean DVH for contralateral kidney. B) mean DVH for small bowel and small bowel -
PTV. C) Small bowel DVH results for all cases. D) Small bowel-PTV DVH results for all cases.
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studies.
Another important point is the reduction achieved in
delivery time, which is a major advantage of RapidArc.
Even if static gantry IMRT allows acceptable dose distri-
bution, the average fraction time is about 20 minutes
[13,20]. Shorter treatment ti m ew i l lr e d u c et h el i k e l i -
hood of intrafraction baseline shifts in PTV and organs
at risk position. Taking into account that those patients
are painful in most of the cases because of the psoas
invasion and have big difficulties to stay laying on the
accelerator table, RapidArc technology offers a solution
improving treatment comfort and decreasing the possi-
bility of set-up errors.
Even if the available evidence from retrospective stu-
dies and prospective non randomized trials strongly sug-
gests that conventional preoperative radiation is better
tolerated, we treated using RapidArc technology two
patients of the postoperative group with excellent clini-
cal tolerance.
Conclusions
RapidArc for retroperitoneal sarcomas achieved accepta-
ble dosimetric results in preoperative or postoperative
setting, even for large volumes. The two first treated
patients presented a good tolerability. Currently, we are
continuing to treat patients with this technique offering
a rapid and safe procedure. Longer follow-up is war-
ranted to assess long-term toxicity and local control.
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